Today: 19 March 2026
Subscribe
Browse Category

LSE:EZJ.L 3 November 2025 - 7 March 2026

FTSE 100 reels from worst week in a year as oil shock hits London stocks

FTSE 100 reels from worst week in a year as oil shock hits London stocks

The FTSE 100 dropped 5.7% this week, its sharpest fall since April 2025, as oil surged above $90 a barrel and traders slashed UK rate-cut bets. Energy and defence shares held firm, but airlines and miners tumbled. The FTSE 250 lost 0.8% on Friday. Money markets now see little chance of a March Bank of England cut.
7 March 2026
········
FTSE 100 rises as miners lift London stocks; 3i soars, Lloyds upgrades targets

FTSE 100 rises as miners lift London stocks; 3i soars, Lloyds upgrades targets

London’s FTSE 100 rose 0.44% to 10,198.75 by 1105 GMT, led by mining and financial stocks. Gold surged near $5,600 an ounce, hitting new highs as investors sought safe havens amid geopolitical tensions and a weaker dollar. 3i Group jumped 14% after strong results from Action, while Lloyds gained 0.5% on a profit beat and new share buyback. Sterling hovered near multi-year highs against the dollar.
29 January 2026
····
UK Stock Market Today, 24 November 2025: FTSE 100 Ends Flat as Defence Stocks Slide but Banks and Miners Advance

UK Stock Market Today, 24 November 2025: FTSE 100 Ends Flat as Defence Stocks Slide but Banks and Miners Advance

The FTSE 100 closed nearly flat at 9,534.91, down 0.05% on Monday, while the FTSE 250 rose 0.23%, ending an eight-day losing streak. Defence stocks fell on signs of Ukraine peace talks, but banks and gold miners rallied on U.S. rate-cut hopes. Investors remained cautious ahead of Wednesday’s UK Budget.
25 November 2025
············
London Stock Exchange at Record Highs – Inside the Historic Market’s Brexit Battle and 2025 Revival

London Markets Slip as FTSE 100 Falters Ahead of BoE Verdict

The FTSE 100 closed at 9,701, down 0.2%, pausing near record highs as gains in oil and financial stocks were offset by losses in mining and retail. The FTSE 250 slipped 0.3%. Investors grew cautious ahead of Thursday’s Bank of England meeting. Vodafone fell over 5% after a broker downgrade, while BP rose 1% after a $1.5 billion US asset sale.
3 November 2025
·······

Stock Market Today

  • Soligenix Publishes HyBryte Clinical Data Validating Safety and Efficacy
    March 19, 2026, 2:04 PM EDT. Soligenix (NASDAQ: SNGX), a biopharmaceutical firm targeting rare diseases, reported the publication of clinical trial data on HyBryte (synthetic hypericin) in the peer-reviewed journal Expert Opinion on Investigational Drugs. The summary underscores HyBryte's safety profile, non-mutagenic mechanism, and demonstrated efficacy against cutaneous T-cell lymphoma (CTCL). The data supports HyBryte's potential as a first-line treatment. Soligenix continues its ongoing FLASH2 Phase 3 trial for HyBryte, with an interim analysis slated for Q2 2026. The company focuses on rare disease therapies and vaccine programs underpinned by proprietary technology. This publication bolsters investor confidence as Soligenix advances regulatory efforts toward global commercialization of HyBryte, expanding its pipeline across inflammatory and infectious diseases.
Go toTop